

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 211/60		A1	(11) International Publication Number: WO 96/12699 (43) International Publication Date: 2 May 1996 (02.05.96)
(21) International Application Number: PCT/GB95/02513		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(22) International Filing Date: 23 October 1995 (23.10.95)			
(30) Priority Data: 9421476.4 25 October 1994 (25.10.94) GB 9504926.8 10 March 1995 (10.03.95) GB			
(71) Applicant (for all designated States except US): CHIRO-SCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): LANGSTON, Marianne [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). SKEAD, Benjamin, Mark [GB/GB]; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).			
(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).			

(54) Title: CRYSTALLISATION OF LEVOBUPIVACAIN AND ANALOGUES THEREOF**(57) Abstract**

Levobupivacaine or an analogue thereof is prepared by reaction with a tartaric acid resolving agent in a solvent, in the presence of water and/or less than 0.5 equivalents of the resolving agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CRYSTALLISATION OF LEVOBUPIVACAIN AND ANALOGUES THEREOF
Field of the Invention

This invention relates to a process for the manufacture of analgesic agents such as levobupivacaine, 5 i.e. as substantially single enantiomers, and also analogues thereof.

Background of the Invention

Levobupivacaine and analogues thereof such as ropivacaine are useful as local anaesthetics. These (S)-10 enantiomers are of increasing interest as analgesics having a higher therapeutic index than the corresponding racemates. Known syntheses have various disadvantages.

Tullar et al, J. Med. Chem. 14(9):891-2 (1971), and US-A-4180712, describe the use of natural (R,R)-tartaric 15 acid as the resolving agent for the separation of levobupivacaine and its antipode. 2 Molar equivalents of the base are used per molar equivalent of the acid resolving agent. For the preparation of levobupivacaine on an industrial scale, this is impractical, as the (R)-20 bupivacaine (R,R)-tartrate salt crystallises first, necessitating additional processing and therefore lowering the overall operating efficiency.

Further, for separation of levobupivacaine from its 25 antipode, the method described in the prior art does not give reproducible yields of the tartrate salt, and the diastereomeric excess is variable.

This prior art does not describe a consistently reproducible process. Experiments sometimes failed, using the known conditions.

30 Federsel et al, Acta. Chem. Scand. B41:757-761 (1987), disclose the use of 0.52 equivalents of the resolving agent dibenzoyl tartrate, en route to the (S)-enantiomer of formula I when R=H. Water of crystallisation only is present. The resolving agent is costly.

35 Summary of the Invention

The present invention is based on the surprising discoveries that:-

1. Addition of a low concentration of water, e.g. in the range 0.1-20%, to an alcoholic resolution medium, gives a much more reproducible resolution, allows the process to be run at higher concentrations (typically 20% w/v) and yields 5 levobupivacaine (*S,S*)-tartrate or its antipode at higher optical purity (typically > 98 % diastereomeric excess).
2. Use of less than 0.5 molar equivalents of the resolving agent, preferably 0.25 molar equivalents, yields 10 levobupivacaine (*S,S*)-tartrate or its antipode at higher optical purity (typically > 98% diastereomeric excess), and makes more efficient use of the resolving agent.

In addition:

3. Use of (*S,S*)-tartaric acid, to crystallise out the levobupivacaine (*S,S*)-tartrate salt first, is a more 15 efficient procedure for the preparation of levobupivacaine.
4. Levobupivacaine (*S,S*)-tartrate or its antipode can be converted directly into the hydrochloride salt. This is in contrast to the prior art, which involves the less 20 efficient procedure of forming the desired hydrochloride from free base.

These discoveries can be utilised in connection with all compounds of the formula in claim 1, i.e. pipecolic acid 2,6-dimethylanilide or a N-alkyl derivative. They include optically-enriched bupivacaine, especially 25 levobupivacaine, and ropivacaine.

Description of the Invention

The novel process is preferably conducted in accordance with all the parameters given above. In other respects, conventional crystallisation technology may be 30 used. The reaction is preferably conducted using a C₁₋₆ alkanol, such as isopropanol, as the primary reaction solvent, but any suitable water-miscible organic solvent may be used.

This invention is conveniently operated in conjunction 35 with a racemisation process. Levobupivacaine and its antipode, and analogues thereof, in free base form or as its salts, can be racemised, as described in International

Patent Application No. PCT/GB95/02247, as part of an efficient recycle procedure.

The following Examples illustrate the invention.

Example 1

5 Bupivacaine hydrochloride monohydrate (1 kg, 2.916 mol) was charged to a separator with water (5 l) and TBME (5 l). Sodium hydroxide solution (10 N, 300 ml, 3 mol) was then added, and the reaction mixture was stirred for 5 min until all the solids had dissolved. The stirrer was
10 stopped and the layers were allowed to separate over 0.5 h. The aqueous layer was separated and the organic layer was washed with water (2 l). The organic layer was charged to a vessel configured for atmospheric distillation. TBME (2.5 l) was distilled. Isopropanol was added and the
15 distillation continued until all the TBME had been removed. The total volume of isopropanol remaining should be 4200 ml (1 part bupivacaine base: 5 parts isopropanol). Water (105 ml) and then (S,S)-(-)-tartaric acid (109 g, 0.73 mol, 0.25 eq) were added at 80°C, and the mixture was stirred at 80°C
20 until all the solids had dissolved.

The solution was allowed to cool to 20°C, with slow stirring. If crystallisation had not started when the temperature had reached 65°C then the solution was seeded. The crystals were filtered off and washed twice with
25 isopropanol (2 x 500 ml) and then dried *in vacuo* to give levobupivacaine (S,S)-tartrate (430 g, 80% yield of desired diastereomer at 98% e.e.).

Example 2

30 Levobupivacaine (S,S)-tartrate (50 g, 0.069 mol) was suspended in isopropanol (150 ml) and heated to 50°C. Hydrogen chloride (5 g, 0.14 mol) gas was introduced. The temperature rose to 65°C and the solids dissolved. The mixture was heated to 80°C to ensure complete dissolution. The mixture was cooled to 5°C and a solid crystallised.
35 The solid was filtered off and washed with isopropanol (2 x 50 ml) and dried *in vacuo* to give levobupivacaine hydrochloride (21.9 g, 40%).

Examples 3-14 and Comparative Example A

In order to investigate the criticality of the presence of water and the relative amounts of the compounds of formula (I) and resolving agent, various comparative 5 tests were done. In each of the tests, to racemic bupivacaine free base (20 g) were added IPA (isopropanol; 5 vol) and the given amount of water. The suspension was warmed with stirring. At approximately 75°C, the given amount of tartaric acid was added. The suspension was 10 brought to reflux. Once all the solid had dissolved, the solution was allowed to cool slowly to room temperature. The suspension was filtered and the cake obtained sampled; the sample was treated with aqueous NaOH and the ee of the liberated free base measured by chiral HPLC. The cake was 15 washed with IPA (20 ml). The solid was dried to constant weight in a vacuum oven at 40-50°C.

The results are tabulated below, in respective groups of 5 and 4 tests (each showing the effect of varying the amount of water), and 4 and 3 tests (each showing the 20 effect of varying the amount of resolving agent).


Table

Example	No. equiv. tartaric acid	% Water	% ee after filtration	% ee after wash	yield (g)
A	0.5	0	8.5	38	18.9
3	0.5	1	38	47	16.4
4	0.5	2	82	98	12
5	0.5	3	92	98	11
6	0.5	5	95	99	10.2
7	0.4	0	31	46	17.9
8	0.4	1	48	58	15.4
9	0.4	2	76	88	12.4
10	0.4	3	85	95	11.4
A	0.5	0	8.5	38	18.9
11	0.4	0	31	46	17.9
12	0.3	0	72	84	12.9
13	0.2	0	66	85	9.9
3	0.5	1	38	47	16.4
8	0.4	1	48	58	15.4
14	0.3	1	86	96	11.6

CLAIMS

1. A process of preparing an optically-enriched compound of formula (I)

5



10 wherein R is H or C₁₋₈ alkyl, which comprises reaction with a tartaric acid resolving agent in a solvent, characterised in that the reaction is conducted in the presence of water and/or less than 0.5 equivalents of the resolving agent.

15 2. A process according to claim 1, wherein R is propyl.

3. A process according to claim 1, wherein R is butyl.

4. A process according to any preceding claim, wherein 20 the resolving agent is (S,S)-tartaric acid.

5. A process according to any preceding claim, wherein the solvent comprises a C₁₋₆ alkanol.

6. A process according to any preceding claim, wherein 25 the combination of water and solvent comprises 0.1 to 20% water.

7. A process according to any preceding claim, which comprises using between 0.2 and 0.5 molar equivalents of the resolving agent, per molar equivalent of the compound 25 of formula (I).

8. A process according to any preceding claim, which additionally comprises conversion of the enantiomer to the hydrochloride salt.

9. A process according to any preceding claim, for 30 preparing levobupivacaine.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/02513

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/60

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>J. MED. CHEM., vol. 14, no. 9, 1971 pages 891-892, TULLAR, B. F. 'Optical Isomers of Mepivacaine and Bupivacaine' see the whole document ---</p>	1-9
X	<p>ACTA CHEMICA SCANDINAVICA, vol. B41, no. 10, 1987 pages 757-761, H.-J. FEDERSEL ET. AL. 'An Efficient Synthesis of a New, Chiral 2',6'-Pipecoloxylidide' see the whole document ---</p>	1-9 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *T* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

11 December 1995

Date of mailing of the international search report

19.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORTInternat'l Application No
PCT/GB 95/02513

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANAL. PROFILES DRUG SUBST., vol. 19, 1990 pages 59-94, see page 61 -----	1-9